Bortezomib-Associated Severe Orthostatic Hypotension and Hyponatremia

Bortezomib-Associated Severe Orthostatic Hypotension and Hyponatremia

Bibliographic Details
Main Authors:	Elif Suyanı, Zeynep Akı, Zeynep Arzu Yeğin, Gülsan Türköz Sucak
Format:	Article
Language:	English
Published:	Galenos Publishing House 2012-08-01
Series:	Turkish Journal of Hematology
Subjects:	bortezomib side effect hypotension hyponatremia multiple myeloma
Online Access:	https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-90377

Similar Items

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
by: N. O’Connor-Byrne, et al.
Published: (2019-02-01)

Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide
by: T.B.M. Castro, et al.
Published: (2016-01-01)

Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide
by: T.B.M. Castro, et al.
Published: (2016-05-01)

Effectiveness of bortezomib and bortezomib-containing programs FOR the treatment of recurrent and resistant multiple myeloma
by: T A Mitina, et al.
Published: (2010-07-01)

A feline case of multiple myeloma treated with bortezomib
by: Hiroyuki Tani, et al.
Published: (2022-11-01)

Multiple myelomda kromozomal aberasyonlar: klinik sonuçlar ve bortezomib’ e yanıt
by: Arbil AÇIKALIN, et al.
Published: (2019-06-01)

Evaluation of a Generic Bortezomib Molecule in Newly Diagnosed Multiple Myeloma Patients
by: Sinan Mersin, et al.
Published: (2021-08-01)

Bortezomib-Induced Perimyocarditis in a Multiple Myeloma Patient: A Case Report
by: Yaman Alali, et al.
Published: (2021-12-01)

Reduced weekly subcutaneous doses of bortezomib in combination with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma
by: Farzaneh Ashrafi, et al.
Published: (2020-01-01)

Treatment Outcomes with Reduced-Dose Bortezomib in Adult Patients with Multiple Myeloma: A Single-Center Experience
by: Jeremiah R. Vallente, et al.
Published: (2022-07-01)

Effective response with bortezomib retreatment in relapsed multiple myeloma
by: Christian Taverna, et al.
Published: (2012-04-01)

A Case of Disseminated and Fulminant Plasmacytomas That Developed during Bortezomib Treatment
by: Soo-Young Bae, et al.
Published: (2011-02-01)

Bortezomib neurotoxicity treatment of multiple myeloma: single center experience and literature review
by: N. V. Stepanova, et al.
Published: (2022-11-01)

Incidence, characteristics, and treatments of peripheral neuropathy in multiple myeloma patients receiving bortezomib (velcade)
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Update on the optimal use of bortezomib in the treatment of multiple myeloma
by: Mohan M, et al.
Published: (2017-03-01)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
by: Laura Rosiñol, et al.
Published: (2023-11-01)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
by: Mir Sadaqat Hassan Zafar, et al.
Published: (2018-01-01)

Dose Adjustment Helps Obtain Better Outcomes in Multiple Myeloma Patients with Bortezomib, Melphalan, and Prednisolone (VMP) Treatment
by: Su-Hee Cho, et al.
Published: (2019-05-01)

Results of multiple myeloma treatment with bortezomib
by: T. I. Pospelova, et al.
Published: (2022-11-01)

Bortezomib-Induced Epigenetic Alterations in Nerve Cells: Focus on the Mechanisms Contributing to the Peripheral Neuropathy Development
by: Karolina Łuczkowska, et al.
Published: (2022-02-01)

Prevention and management of bortezomib-induced peripheral neuropathy in patients with multiple myeloma
by: S. V. Semochkin, et al.
Published: (2022-04-01)

Management of Multiple Myeloma and Usage of Bortezomib: Perspective from India and Ukraine
by: India and Ukraine Haemato-oncology Group, et al.
Published: (2016-11-01)

Chalazia development in multiple myeloma: a new complication associated with bortezomib therapy
by: Charles Yun, et al.
Published: (2015-06-01)

Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma
by: Zhihong Zheng, et al.
Published: (2018-02-01)

Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells
by: Tibullo eDaniele, et al.
Published: (2015-10-01)

Progressively invalidating orthostatic hypotension: A common symptom for a challenging diagnosis
by: Serena Pelusi, et al.
Published: (2016-01-01)

Why bortezomib cannot go with ‘green’?
by: Li Jia, et al.
Published: (2013-12-01)

Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma
by: Joseph Han, et al.
Published: (2023-07-01)

Successful treatment with bortezomib-containing regimen of primary plasma cell leukemia: a case report
by: Mohammad Bader Obeidat, et al.
Published: (2020-05-01)

Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy
by: Jeter Ashley, et al.
Published: (2012-08-01)

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
by: Se Ryeon Lee, et al.
Published: (2019-11-01)

Two Secondary Primary Malignancies after Bortezomib Therapy for Multiple Myeloma: A Single-center Experience
by: Tian-Jiao Guo, et al.
Published: (2017-01-01)

Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma
by: Taleb Azarm, et al.
Published: (2012-01-01)

Optimized Liposomal Delivery of Bortezomib for Advancing Treatment of Multiple Myeloma
by: Chi Zhang, et al.
Published: (2023-11-01)

Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
by: Esther A. Zaal, et al.
Published: (2017-08-01)

Cost-effectiveness of bortezomib for multiple myeloma: a systematic review
by: Chen W, et al.
Published: (2016-05-01)

Attenuation of STAT3 Signaling Cascade by Daidzin Can Enhance the Apoptotic Potential of Bortezomib against Multiple Myeloma
by: Min Hee Yang, et al.
Published: (2019-12-01)

Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib‐based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients
by: Yuka Kawaji‐Kanayama, et al.
Published: (2022-02-01)

Bortezomib Pharmacogenetic Biomarkers for the Treatment of Multiple Myeloma: Review and Future Perspectives
by: Antonio Sanz-Solas, et al.
Published: (2023-04-01)

Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1
by: Xiang Zhou, et al.
Published: (2023-05-01)